Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 3.33 USD -5.13% Market Closed
Market Cap: 885.9m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Intrinsic Value

AUTL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AUTL stock under the Base Case scenario is 5.91 USD. Compared to the current market price of 3.33 USD, Autolus Therapeutics PLC is Undervalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AUTL Intrinsic Value
5.91 USD
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Autolus Therapeutics PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AUTL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AUTL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Autolus Therapeutics PLC

Provide an overview of the primary business activities
of Autolus Therapeutics PLC.

What unique competitive advantages
does Autolus Therapeutics PLC hold over its rivals?

What risks and challenges
does Autolus Therapeutics PLC face in the near future?

Summarize the latest earnings call
of Autolus Therapeutics PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Autolus Therapeutics PLC.

Provide P/S
for Autolus Therapeutics PLC.

Provide P/E
for Autolus Therapeutics PLC.

Provide P/OCF
for Autolus Therapeutics PLC.

Provide P/FCFE
for Autolus Therapeutics PLC.

Provide P/B
for Autolus Therapeutics PLC.

Provide EV/S
for Autolus Therapeutics PLC.

Provide EV/GP
for Autolus Therapeutics PLC.

Provide EV/EBITDA
for Autolus Therapeutics PLC.

Provide EV/EBIT
for Autolus Therapeutics PLC.

Provide EV/OCF
for Autolus Therapeutics PLC.

Provide EV/FCFF
for Autolus Therapeutics PLC.

Provide EV/IC
for Autolus Therapeutics PLC.

Show me price targets
for Autolus Therapeutics PLC made by professional analysts.

What are the Revenue projections
for Autolus Therapeutics PLC?

How accurate were the past Revenue estimates
for Autolus Therapeutics PLC?

What are the Net Income projections
for Autolus Therapeutics PLC?

How accurate were the past Net Income estimates
for Autolus Therapeutics PLC?

What are the EPS projections
for Autolus Therapeutics PLC?

How accurate were the past EPS estimates
for Autolus Therapeutics PLC?

What are the EBIT projections
for Autolus Therapeutics PLC?

How accurate were the past EBIT estimates
for Autolus Therapeutics PLC?

Compare the revenue forecasts
for Autolus Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Autolus Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Autolus Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Autolus Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Autolus Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Autolus Therapeutics PLC with its peers.

Analyze the financial leverage
of Autolus Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Autolus Therapeutics PLC.

Provide ROE
for Autolus Therapeutics PLC.

Provide ROA
for Autolus Therapeutics PLC.

Provide ROIC
for Autolus Therapeutics PLC.

Provide ROCE
for Autolus Therapeutics PLC.

Provide Gross Margin
for Autolus Therapeutics PLC.

Provide Operating Margin
for Autolus Therapeutics PLC.

Provide Net Margin
for Autolus Therapeutics PLC.

Provide FCF Margin
for Autolus Therapeutics PLC.

Show all solvency ratios
for Autolus Therapeutics PLC.

Provide D/E Ratio
for Autolus Therapeutics PLC.

Provide D/A Ratio
for Autolus Therapeutics PLC.

Provide Interest Coverage Ratio
for Autolus Therapeutics PLC.

Provide Altman Z-Score Ratio
for Autolus Therapeutics PLC.

Provide Quick Ratio
for Autolus Therapeutics PLC.

Provide Current Ratio
for Autolus Therapeutics PLC.

Provide Cash Ratio
for Autolus Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Autolus Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Autolus Therapeutics PLC?

What is the current Free Cash Flow
of Autolus Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Autolus Therapeutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Autolus Therapeutics PLC

Current Assets 804.3m
Cash & Short-Term Investments 758.5m
Receivables 32m
Other Current Assets 13.8m
Non-Current Assets 97.1m
PP&E 92.5m
Other Non-Current Assets 4.6m
Current Liabilities 44m
Accounts Payable 1.4m
Accrued Liabilities 42m
Other Current Liabilities 570k
Non-Current Liabilities 275.4m
Other Non-Current Liabilities 275.4m
Efficiency

Earnings Waterfall
Autolus Therapeutics PLC

Revenue
10.5m USD
Operating Expenses
-185.5m USD
Operating Income
-175m USD
Other Expenses
-46.3m USD
Net Income
-221.3m USD

Free Cash Flow Analysis
Autolus Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Autolus Therapeutics is making significant strides with obe-cel, focusing on regulatory reviews in the U.S., Europe, and now the U.K., with a PDUFA date set for November 16th. The company is running two promising Phase 1 trials for pediatric ALL and advanced systemic lupus. Financially, Autolus ended Q2 2024 with $705.9 million in cash, up from $239.6 million last year, despite a rise in net operating expenses to $58.9 million from $44.4 million in Q2 2023. With strong cash reserves, Autolus is well-capitalized to launch obe-cel and advance its pipeline .

What is Earnings Call?
Fundamental Scores

AUTL Profitability Score
Profitability Due Diligence

Autolus Therapeutics PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
28/100
Profitability
Score

Autolus Therapeutics PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

AUTL Solvency Score
Solvency Due Diligence

Autolus Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
62/100
Solvency
Score

Autolus Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AUTL Price Targets Summary
Autolus Therapeutics PLC

Wall Street analysts forecast AUTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUTL is 10.61 USD with a low forecast of 7.07 USD and a high forecast of 13.65 USD.

Lowest
Price Target
7.07 USD
112% Upside
Average
Price Target
10.61 USD
219% Upside
Highest
Price Target
13.65 USD
310% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AUTL?

Click here to dive deeper.

Dividends

Autolus Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AUTL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

AUTL News

Profile

Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

885.9m USD

Dividend Yield

0%

Description

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

Contact

London
The Mediaworks, 191 Wood Lane
+442038296230.0
www.autolus.com

IPO

2018-06-22

Employees

324

Officers

CEO & Director
Dr. Christian Martin Itin Ph.D.
Founder, Senior VP & Chief Scientific Officer
Dr. Martin Pule M.D., MBBS
Senior VP & CFO
Mr. Robert F. Dolski
Senior VP & COO
Mr. Christopher Vann
Senior VP & Chief Technical Officer
Mr. David Brochu
Senior VP & Chief Human Resources Officer
Mr. Alexander Swan
Show More
Senior VP, Chief Commercial Officer & Site Head of US
Mr. Brent Rice
Director of Investor Relations
Ms. Olivia Manser
Senior VP of Legal Affairs & General Counsel and Secretary
Mr. Alex Driggs
Senior VP & Chief Business Development Officer
Dr. Chris Williams
Show Less

See Also

Discover More
What is the Intrinsic Value of one AUTL stock?

The intrinsic value of one AUTL stock under the Base Case scenario is 5.91 USD.

Is AUTL stock undervalued or overvalued?

Compared to the current market price of 3.33 USD, Autolus Therapeutics PLC is Undervalued by 44%.

Back to Top